Free Trial

Appili Therapeutics Q1 2024 Earnings Report

Appili Therapeutics logo
$0.03 +0.00 (+0.39%)
(As of 12/20/2024 05:55 PM ET)

Appili Therapeutics EPS Results

Actual EPS
-$0.01
Consensus EPS
-$0.02
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Appili Therapeutics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Appili Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Appili Therapeutics Earnings Headlines

Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
See More Appili Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Appili Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Appili Therapeutics and other key companies, straight to your email.

About Appili Therapeutics

Appili Therapeutics (OTCMKTS:APLIF), a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.

View Appili Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings